Clonazepam
| Evidence Level: L3 | Predicted Indications: 3 |
Table of Contents
- Clonazepam
- Pharmacist Assessment Report
- Clonazepam: GABA-A receptor positive modulator (benzodiazepine) → restless legs syndrome
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Clonazepam: GABA-A receptor positive modulator (benzodiazepine) → restless legs syndrome
One-Sentence Summary
Clonazepam is a benzodiazepine marketed in Canada under several brand and generic names. The TxGNN model predicts it may be effective for restless legs syndrome, with a score of 0.9965. No clinical trials are registered in the data compiled for this report, but 20 publications are listed, including a Cochrane systematic review and a 2025 clinical practice guideline.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | restless legs syndrome |
| TxGNN Prediction Score | 0.9965 |
| Evidence Level | L3 |
| Canada Market Status | Marketed (marketed DINs: 8 of 11; dormant: 3) |
| Number of DINs | 11 (marketed: 8) |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the data compiled for this report. Clonazepam belongs to the benzodiazepine class, which enhances GABA-A receptor-mediated inhibition. This may reduce the sensory-motor hyperexcitability and sleep fragmentation associated with restless legs syndrome (RLS) and periodic limb movements.
The literature shows long-standing clinical use of clonazepam in RLS. A small 1984 randomized double-blind crossover trial versus placebo (6 patients) reported improved subjective sleep quality and leg dysaesthesia. A placebo-controlled sleep laboratory study of 1 mg clonazepam (2001) and a 2024 historical overview of benzodiazepines in RLS also address this use.
Benzodiazepines are not first-line treatment, though. The 2025 American Academy of Sleep Medicine guideline places them below first-line agents such as alpha-2-delta ligands and iron therapy, so they should not be treated as equivalent. The high TxGNN score is consistent with this existing clinical use, but it is a computational prediction and not clinical proof.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 39324694 | 2025 | Guideline | J Clin Sleep Med | AASM clinical practice guideline on treating RLS and periodic limb movement disorder in adults and children |
| 28319266 | 2017 | Systematic review | Cochrane Database Syst Rev | Benzodiazepines, particularly clonazepam, are used for RLS; review of their evidence |
| 38708125 | 2024 | Review | Tremor Other Hyperkinet Mov | Historical overview; about 25% of treated RLS patients receive benzodiazepines; 17 articles on clonazepam in RLS |
| 18925578 | 2008 | Review | Mov Disord | Movement Disorder Society evidence-based review of RLS treatments |
| 36692194 | 2023 | Systematic review and meta-analysis | J Clin Sleep Med | Which drug classes suppress periodic limb movements in RLS |
| 6380197 | 1984 | Randomized crossover trial | Acta Neurol Scand | In 6 patients, clonazepam significantly improved sleep quality and leg dysaesthesia versus placebo; vibration effect not significant |
| 11313161 | 2001 | Placebo-controlled sleep lab study | Eur Neuropsychopharmacol | Acute effects of 1 mg clonazepam on sleep and awakening quality in RLS and PLMD |
| 20156514 | 2010 | Clinical study | Prog Neuropsychopharmacol Biol Psychiatry | Proposed dose equivalence between clonazepam and pramipexole in RLS |
| 39787099 | 2025 | Clinical study | Sleep | Compared effects of dopamine agonists and clonazepam on large muscle group movements in RLS |
| 24363103 | 2014 | Review | Neurotherapeutics | Overview of changes in RLS treatment |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 00382825 | RIVOTRIL | Not recorded | Not recorded |
| 00382841 | RIVOTRIL | Not recorded | Not recorded |
| 02177897 | APO-CLONAZEPAM | Not recorded | Not recorded |
| 02177889 | APO-CLONAZEPAM | Not recorded | Not recorded |
| 02179660 | PMS-CLONAZEPAM | Not recorded | Not recorded |
Safety Considerations
- Drug Interactions: 100 interactions are recorded. Major interactions include morphine and liposomal morphine. Moderate interactions include bupropion, aprepitant, omeprazole, cimetidine, clarithromycin, dronabinol, metoclopramide, nabilone, opium, sibutramine and teduglutide. Antacids (magnesium oxide, aluminum hydroxide, calcium carbonate, magaldrate) are minor.
- Conditions flagged in the data as contraindicated (not from label text): liver failure and liver disease, kidney disease, porphyria, angle-closure and open-angle glaucoma, sleep apnea syndromes, respiratory failure, and substance-related disorders or dependence.
- Class concerns: dependence, tolerance, cognitive impairment and falls, especially in older patients. Please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Clonazepam has long-standing clinical use in restless legs syndrome, supported by a Cochrane systematic review, a small placebo-controlled crossover trial and reviews. However, the current guideline ranks it below first-line therapies, and no registered trials were found.
To proceed, the following is needed:
- Confirmation of the underlying study designs and sizes (RCT versus small or open-label studies)
- Health Canada package insert warnings and contraindications
- Mechanism-of-action data from DrugBank
- A plan for positioning clonazepam against first-line RLS therapies, with dependence and fall-risk monitoring
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.